ArticlePloS one2026
A nationwide survey on the prevalence of asbestos-related lung cancer in Japan.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nationwide prevalence of asbestos-related lung cancer (ARLC) needs to be accurately estimated to adequately operate a compensation subsidy program for patients with ARLC. In the present study, we aimed to estimate the proportion of patients with ARLC among patients with primary lung cancer according to the criteria established in the Japanese national compensation system, and described the characteristics and distribution of ARLC,. All facilities that treated patients diagnosed with lung cancer in 2016 were requested to submit computed tomography (CT) images of ten patients who were randomly selected from the national databases of hospital-based cancer registries. ARLC was defined as pleural plaques (PPs) extending over one-quarter of the inner lateral chest wall or existing PPs accompanied by obvious lung fibrosis. We estimated the proportion and distribution of ARLC among primary lung cancer cases and compared the characteristics of ARLC with those of primary lung cancer. Of the 772 facilities that treated at least one patient with lung cancer, 370 facilities provided 3,565 sets of CT images. Among them, 216 (6.1%) patients had PPs, and 86 (2.4%) patients met the compensation criteria. After sample weighting, 2.0% of all primary lung cancers were classified as ARLC in Japan. Compared with other primary lung cancers, a higher percentage of patients with ARLC were male (94.2% vs. 68.6%; P < 0.01) and had more advanced-stage disease (stage III: 22.1% vs. 16.0%; stage IV: 44.2% vs. 39.8%; P = 0.05). Most patients with ARLC (53.5%) were diagnosed at designated cancer hospitals. The proportion of patients with squamous cell carcinoma was higher in patients with ARLC than in those with primary lung cancer (25.6% vs. 18.6%; P < 0.01). The estimated number of patients with ARLC was higher than expected from the number of applicants in the Asbestos Health Damage Relief System for asbestos-related health damages. Thus, countermeasures are needed to accurately identify eligible compensation recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.